Services we offer

We can become your trusted partner for the clinical development of your infectious disease compounds.

All services

Early-phase clinical research

(regulatory-compliant)

What we do

  • First-in-human (FIH), safety & immunogenicity, SAD/MAD, and dose-finding studies
  • Participant recruitment & retention
  • Study design and protocol development
  • Clinical conduct in accordance with ICH-GCP
  • Data management & biostatistics

Development of novel clinical research methodologies

What we do

  • Biomarker strategy and validation
  • Controlled Human Infection Models (CHIMs)

How we work

We are internationally recognized for CHIM expertise. When appropriate and ethically approved, CHIMs can substantially accelerate infectious-disease product development by enabling early, decision-quality read-outs. Curious whether a CHIM fits your program? Please get in touch, we are happy to explore options with you.

Laboratory support

What we do

  • PBMC isolation
  • Mucosal and other clinical sample processing
  • Safety laboratory testing
  • Microbiological assays

Early-phase development & end-to-end consulting

What we do

  • Clinical development planning for drugs and vaccines
  • Regulatory & ethics support (scientific advice, submissions, responses)
  • Step-by-step roadmaps to marketing authorization/licensure with indicative vendor quotes

How we work

Building on decades of experience in early-phase development, we help map the path from candidate to first-in-human and beyond. We prepare for and facilitate interactions with Dutch or European regulators and ethics committees and can provide a clear overview of required work packages, budgets, and timelines.

Why choose INFECTA

We are deeply invested in our clients’ success because we understand that life-saving infectious disease products need to reach patients quickly and cost-effectively. Our approach combines rigorous quality standards with an innovative mindset that identifies pragmatic solutions others might overlook. This combination of scientific rigor and strategic thinking has established our reputation for delivering results that matter.

Globally largest CHIM portfolio

Capacity to produce, establish and validate new CHIMs ​

Not-for-profit base with focus on social impact

Large academic network

 

Any questions regarding the services?

Contact us with the form, or reach out to info@infecta.org

 

Let’s accelerate the development of your infectious disease product together